lbeveridge

[Proceedings of The National Academy of Sciences of The United States of America] Using an immunocompetent autologous breast cancer model, the authors investigated a MAtrix REgulating MOtif-mimicking peptide, which inhibited the protumorigenic ECM molecule tenascin-C that activated several cancer hallmarks.

[Regenity Biosciences (BioSpace)] Regenity Biosciences announced that it has received FDA 510(k) clearance to market RejuvaKnee, a minimally invasive collagen-based meniscal implant indicated for use in the reinforcement and repair of soft tissue injuries of the meniscus.

[Stony Brook University] Dr. Yi-Xian Qin, Stony Brook University Distinguished Professor and Chair of the Department of Biomedical Engineering in the Renaissance School of Medicine and in the College of Engineering and Applied Sciences at Stony Brook University, will receive the 2025 Biomedical Engineering Society Christopher Jacobs Award for Excellence in Leadership.

[Nature Medicine] A Phase III EMBARK study aimed to assess the efficacy and safety of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) was conducted . Ambulatory males with DMD, ≥4 years to <8 years of age, were randomized and stratified by age group and North Star Ambulatory Assessment score to single-administration intravenous delandistrogene moxeparvovec or placebo.

[Blood Cancer Journal] Plerixafor was given subcutaneously followed 2 h later by MGTA-145 intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6×106 CD34+ cells/kg.

[Blood Cancer Journal] Scientists found significant correlation between DEK expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration.